EP2663306A4 - Polymorphs of dexlansoprazole salts - Google Patents

Polymorphs of dexlansoprazole salts

Info

Publication number
EP2663306A4
EP2663306A4 EP11855797.4A EP11855797A EP2663306A4 EP 2663306 A4 EP2663306 A4 EP 2663306A4 EP 11855797 A EP11855797 A EP 11855797A EP 2663306 A4 EP2663306 A4 EP 2663306A4
Authority
EP
European Patent Office
Prior art keywords
dexlansoprazole
polymorphs
salts
dexlansoprazole salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11855797.4A
Other languages
German (de)
French (fr)
Other versions
EP2663306A1 (en
Inventor
Reddy Bandi Parthasaradhi
Reddy Kura Rathnakar
Reddy Dasari Muralidhara
Reddy Matta Ramakrishna
Krishna Bandi Vamsi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Research Foundation
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Publication of EP2663306A1 publication Critical patent/EP2663306A1/en
Publication of EP2663306A4 publication Critical patent/EP2663306A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11855797.4A 2011-01-12 2011-11-11 Polymorphs of dexlansoprazole salts Withdrawn EP2663306A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN102CH2011 2011-01-12
PCT/IN2011/000782 WO2012095859A1 (en) 2011-01-12 2011-11-11 Polymorphs of dexlansoprazole salts

Publications (2)

Publication Number Publication Date
EP2663306A1 EP2663306A1 (en) 2013-11-20
EP2663306A4 true EP2663306A4 (en) 2014-01-01

Family

ID=46506821

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11855797.4A Withdrawn EP2663306A4 (en) 2011-01-12 2011-11-11 Polymorphs of dexlansoprazole salts

Country Status (2)

Country Link
EP (1) EP2663306A4 (en)
WO (1) WO2012095859A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103788068B (en) * 2014-02-26 2016-04-06 南京海融医药科技有限公司 Dystectic chiral benzimidazole compound sodium salt, preparation method and its usage
CN106749186B (en) * 2016-12-29 2019-03-05 南京海融制药有限公司 A kind of novel crystal forms and preparation method thereof of R-lansoprazole sodium
CN106668018B (en) * 2016-12-29 2019-12-06 南京海融制药有限公司 Dexlansoprazole sodium sustained-release capsule and preparation method thereof
CN106619520B (en) * 2016-12-29 2019-08-06 南京海融制药有限公司 A kind of dry suspensoid agent and preparation method thereof of R-lansoprazole sodium
CN106727381B (en) * 2016-12-29 2020-07-07 南京海融制药有限公司 Orally disintegrating tablet of dexlansoprazole sodium and preparation method thereof
CN109836413A (en) * 2017-11-27 2019-06-04 银谷制药有限责任公司 A kind of Dexlansoprazole sodium crystal and its preparation method and application

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078729A1 (en) * 1999-06-18 2000-12-28 Instytut Farmaceutyczny Crystalline forms of lansoprazole
WO2003082857A2 (en) * 2002-03-27 2003-10-09 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
WO2004083200A1 (en) * 1999-06-17 2004-09-30 Akira Fujishima Crystalline form of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
EP1889841A1 (en) * 2005-06-07 2008-02-20 Takeda Pharmaceutical Company Limited Crystal of salt of benzimidazole compound
WO2009087672A1 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
EP2216333A2 (en) * 2009-02-06 2010-08-11 Dipharma Francis S.r.l. Crystalline forms of Dexlansoprazole
WO2011121546A1 (en) * 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Salts of dexlansoprazole and their preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104470A (en) * 1977-06-03 1978-08-01 Eli Lilly And Company Crystallization process for cefazolin sodium
WO2002012225A1 (en) * 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Salts of benzimidazole compound and use thereof
WO2004056804A2 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
WO2006069159A2 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2007122686A1 (en) * 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. Benzimidazole compounds
MX2010010049A (en) * 2008-03-18 2010-10-04 Reddys Lab Ltd Dr Dexlansoprazole process and polymorphs.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083200A1 (en) * 1999-06-17 2004-09-30 Akira Fujishima Crystalline form of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
WO2000078729A1 (en) * 1999-06-18 2000-12-28 Instytut Farmaceutyczny Crystalline forms of lansoprazole
WO2003082857A2 (en) * 2002-03-27 2003-10-09 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
EP1889841A1 (en) * 2005-06-07 2008-02-20 Takeda Pharmaceutical Company Limited Crystal of salt of benzimidazole compound
WO2009087672A1 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
EP2216333A2 (en) * 2009-02-06 2010-08-11 Dipharma Francis S.r.l. Crystalline forms of Dexlansoprazole
WO2011121546A1 (en) * 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Salts of dexlansoprazole and their preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012095859A1 *

Also Published As

Publication number Publication date
WO2012095859A1 (en) 2012-07-19
EP2663306A1 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
CO6960542A2 (en) Polymorphs of kinase inhibitors
IL232599A (en) Hydrobromide salt of pridopidine
SI2707368T1 (en) Polymorph of linagliptin benzoate
EP2709609A4 (en) Heterocyclic compounds
IL230976A0 (en) Crystalline forms of cabazitaxel
HK1195770A1 (en) Amorphous solid salts of cobicistat (gs-9350) (cobicistat)(gs-9350)
HK1201271A1 (en) Kinase inhibitor polymorphs
GB201304499D0 (en) Carcainium Salts
EP2776393A4 (en) Nampt inhibitors
EP2760853A4 (en) Novel salts of alogliptin
SG11201400452TA (en) Derivatives of xanthone compounds
EP2800747A4 (en) Polymorphs of perampanel
EP2758387A4 (en) Pyridine compounds as inhibitors of kinase
PL3287131T3 (en) Therapeutic uses of ectoine
ZA201308160B (en) Crystalline salts of asenapine
GB201120644D0 (en) Herbicidal uses of compounds
HK1203355A1 (en) Uses of 4-desferrithiocin analogs 4-
EP2663306A4 (en) Polymorphs of dexlansoprazole salts
SI2751081T1 (en) Polymorphic form of pitavastatin calcium
EP2785766A4 (en) Hydroxypolyamine salts
EP2694705A4 (en) Microfrabication of tunnels
EP2688649A4 (en) Polymorphs of lenalidomide
EP2680843A4 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds
EP2684869A4 (en) Preparation of 3-mercaptopropionates
IL230977A (en) Crystalline form of rilapladib

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130724

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20131129

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4439 20060101ALI20131125BHEP

Ipc: C07D 401/12 20060101AFI20131125BHEP

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140603